Friday , March 29 2024
Home / The Angry Bear / Remdesivir V

Remdesivir V

Summary:
This is interesting. In addition to the two huge multi center phase III trials of Remdesivir for Covid 19 with estimated completion some time in May 2020, there is a smaller but very large trial in Beijing with estimated completion May 1 2020. The East is Remd ! May Day May Day May Day “Estimated Study Completion Date : May 1, 2020” Finally there is a very large trial in Hubei province with estimation completion date April 27 2020 “Estimated Study Completion Date : April 27, 2020” Also there is expanded access already. This is instead of individual requests or compassionate use. Note that one exclusion criterion is eligibility for a controlled trial — people will have to risk getting placebo, because they are eligible for a trial. I think this is ethical.

Topics:
Robert Waldmann considers the following as important: ,

This could be interesting, too:

Joel Eissenberg writes You can’t fool Mother Nature

Angry Bear writes Correcting 11 Washington Post’s Charts That Are Supposed to Tell How the Economy Changed Since Covid

NewDealdemocrat writes A detailed look at manufacturing, and an update on freight

Joel Eissenberg writes Is this true?

This is interesting. In addition to the two huge multi center phase III trials of Remdesivir for Covid 19 with estimated completion some time in May 2020, there is a smaller but very large trial in Beijing with estimated completion May 1 2020. The East is Remd ! May Day May Day May Day
“Estimated Study Completion Date : May 1, 2020”

Finally there is a very large trial in Hubei province with estimation completion date April 27 2020
“Estimated Study Completion Date : April 27, 2020”

Also there is expanded access already. This is instead of individual requests or compassionate use. Note that one exclusion criterion is eligibility for a controlled trial — people will have to risk getting placebo, because they are eligible for a trial.
Remdesivir V

I think this is ethical. You read it here.

On the other hand, they only have enough Remdesivir for 30,000 patients

we have proactively and rapidly scaled our supply chain. As of late March, using the active ingredient we already had in our inventory, we have increased our supply to more than 30,000 patient courses of remdesivir on hand, assuming a 10-day course of treatment for patients.

The synthesis takes time and requires reagents which are in short supply, so they can’t scale up immediately

Our goal is to produce a total of:

More than 140,000 treatment courses by the end of May 2020
More than 500,000 treatment courses by October 2020
More than 1 million treatment courses by December 2020
Several million treatment courses in 2021, if required

Capacity Expansion through External Manufacturing

We have supplemented our internal manufacturing with significant additional capacity from multiple manufacturing partners in North America, Europe and Asia. Through these efforts, we believe we have created a manufacturing network capable of producing large volumes of remdesivir at the fastest pace feasible.

I think this is a case for some Defence Production Act_ion.

Robert Waldmann
Robert J. Waldmann is a Professor of Economics at Univeristy of Rome “Tor Vergata” and received his PhD in Economics from Harvard University. Robert runs his personal blog and is an active contributor to Angrybear.

Leave a Reply

Your email address will not be published. Required fields are marked *